Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Secures up to $11 Million from Royalty Sales
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
Relief Therapeutics Announces Executive Changes
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
Relief Therapeutics has Published its Annual Report
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Relief Therapeutics Announces CEO Transition
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
Relief Therapeutics to Participate in Virtual Investor Conferences in January
Relief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16th
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
Relief Reports Half-Year 2021 Results and Provides Corporate Update
Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
RLFTF Stock Increases Over 29% Intraday: Why It Happened
RLFTF Stock Price: 10.25% Increase Explanation